Citigroup Maintains Buy on Sarepta Therapeutics, Raises Price Target to $204
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Neena Bitritto-Garg maintains a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) and raises the price target from $161 to $204.
June 23, 2023 | 4:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup analyst maintains Buy rating on Sarepta Therapeutics and raises price target from $161 to $204.
The news of Citigroup maintaining a Buy rating and raising the price target for Sarepta Therapeutics is likely to have a positive impact on the stock price in the short term. Investors may see this as a sign of confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100